At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
BMS-986205 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986205 and Nivolumab for Advanced Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedJan 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedJan 3, 2019
Enrollment StartDec 31, 2018
Primary CompletionDec 18, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.5 years ago
Interventions
BMS-986205drug
Specified Dose on Specified Day
Nivolumabbiological
Specified Dose on Specified Day